- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Rentschler Biopharma: A 50-year Legacy of Exceptional CDMO Expertise
Published on:
Rentschler Biopharma
Sponsored
Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies
Benedikt von Braunmühl (CEO) and Federico Pollano (vice president of business development) at Rentschler Biopharma explain what sets their CDMO apart. Viewers will learn about:
- What exceptional CDMO expertise means: 25% of all FDA approved biopharmaceuticals in 2023 were supported by the company
- Rentschler Biopharma’s US offerings, as well as commercial and development expertise
- How the company is leveraging its expertise in the field of gene therapy